Otolith’s device is a wearable medical device with FDA Breakthrough Designation. Utilizing our non-invasive Vestibular Resonance Therapy or nVRT technology — the Otolith device provides precision signals which may reduce the disorientation handicap in chronic vertigo individuals, allowing them to maintain tasks of daily living.

An estimated 11.6 million American adults have chronic vertigo related to vertigo from various vestibular disorders. Chronic vertigo develops from the inconsistencies in broader vestibular system and the rest of the neural inputs for a person’s usual orientation and/or balance. Symptoms from these chronic conditions can impact daily living through functional, emotional, and physical handicaps.

Otolith Labs has pioneered nVRT technology. Our core technology uses a patented transducer to send consistent and noninformative stimuli to the vestibular system which may mitigate the sensation of vertigo or dizziness. 

It has been recorded in clinical studies as reliable and durable. We look to make a De Novo submission to the FDA through our ongoing clinical studies.